Researcher
Maria Debiec-Rychter
- Disciplines:Genetics, Systems biology, Molecular and cell biology
Affiliations
- Laboratory for Genetics of Malignant Disorders (Division)
Member
From1 Jul 2009 → Today - Department of Human Genetics (Department)
Member
From1 Oct 1999 → 30 Jun 2009
Projects
1 - 4 of 4
- Human soft tissue sarcomas xenograft mouse models as an opportunity to improve the therapeutic options for patients.From1 Jan 2011 → 31 Dec 2014Funding: FWO research project
- Identification of novel protein kinase targets for the improvement of gastrointestinal stromal tumor (GIST) therapy: a paradigm for the optimisation of kinase targeted therapies.From1 Jan 2011 → 31 Dec 2016Funding: FWO research project
- Deregulated signaling pathways in cancer: from genetic insights towards targeted therapy.From1 Oct 2010 → 30 Nov 2016Funding: BOF - Concerted Research Project from 1994
- The biological and therapeutic importance of CCK-2/gastrin receptor in gastrointestinal stromal tumors (GISTs).From1 Jan 2009 → 31 Dec 2012Funding: FWO research project
Publications
21 - 30 of 193
- PLX9486 shows anti-tumor efficacy in patient-derived, tyrosine kinase inhibitor-resistant KIT-mutant xenograft models of gastrointestinal stromal tumors(2019)
Authors: Agnieszka Wozniak, Maria Debiec-Rychter, Raf Sciot, Patrick Schöffski
Pages: 201 - 210 - Genomic aberrations in cell cycle genes predict progression of KIT-mutant gastrointestinal stromal tumors (GISTs)(2019)
Authors: Maria Debiec-Rychter, Barbara Dewaele
- Discovery and Characterization of Recurrent, Targetable ALK Fusions in Leiomyosarcoma(2019)
Authors: Maria Debiec-Rychter
Pages: 676 - 685 - Activity and safety of crizotinib in patients with advanced clear-cell sarcoma with MET alterations: European Organization for Research and Treatment of Cancer phase II trial 90101 'CREATE' (vol 28, pg 3000, 2017)(2019)
Authors: Patrick Schöffski, A Wozniak, S Stacchiotti, P Rutkowski, J-Y Blay, LH Lindner, SJ Strauss, A Anthoney, F Duffaud, S Richter, et al.
Pages: 344 - 344 - Robust Activity of Avapritinib, Potent and Highly Selective Inhibitor of Mutated KIT, in Patient-derived Xenograft Models of Gastrointestinal Stromal Tumors(2019)
Authors: Agnieszka Wozniak, Maria Debiec-Rychter, Raf Sciot, Patrick Schöffski
Pages: 609 - 618 - Successful Perioperative and Surgical Treatment of a Rare Case of Extra-Gastrointestinal Stromal Tumor Arising in the Prostate Gland(2019)
Authors: Patrick Schöffski, Raf Sciot, Maria Debiec-Rychter, Steven Joniau
Pages: 183 - 191 - Retrospective Analysis of Patients with Advanced Liposarcoma in a Tertiary Referral Center(2019)
Authors: Agnieszka Wozniak, Daphne Hompes, Raf Sciot, Maria Debiec-Rychter, Patrick Schöffski
Pages: 396 - 403 - A Case of Undifferentiated Sarcoma in the Superior Vena Cava and Bilateral Cervical Veins(2018)
Authors: Maria Debiec-Rychter
Pages: 1507 - 1514 - Toward Minimal Residual Disease-Directed Therapy in Melanoma(2018)
Authors: Aljosja Rogiers, Michael Dewaele, Panagiotis Karras, Daniel Brown, Maria Debiec-Rychter, Carmen Adriaens, Oliver Bechter, Joost van den Oord, Thierry Voet, Stein Aerts, et al.
Pages: 843 - + - Crizotinib in patients with advanced, inoperable inflammatory myofibroblastic tumours with and without anaplastic lymphoma kinase gene alterations (European Organisation for Research and Treatment of Cancer 90101 CREATE): a multicentre, single-drug, prospective, non-randomised phase 2 trial(2018)
Authors: Patrick Schöffski, Maria Debiec-Rychter, Raf Sciot, Agnieszka Wozniak
Pages: 431 - 441